Connect Biopharma is trading 17% up at $2.75 in pre-market, primarily driven by recent positive analyst coverage and continued clinical progress for its lead candidate. * Oppenheimer initiated coverage on July 9, 2026, with an Outperform rating and a $8.00 price target, alongside Piper Sandler's "Overweight" rating, highlighting rademikibart's potential. * The company completed enrollment for its Phase 2 Seabreeze STAT Asthma study in June 2026, with topline data anticipated in early September 2026, boosting investor confidence in its development pipeline.